Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Medicamentos de doble y triple propósito para el tratamiento de enfermedades del sistema nervioso central

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20160120002
Publicado:
16/02/2016
Caducidad:
16/02/2017
Resumen:
Una universidad alemana ha desarrollado un medicamento con doble y triple propósito para el tratamiento de enfermedades del sistema nervioso central (SNC). Este medicamento mejora el cumplimiento y tiene menos efectos secundarios y toxicidad. Otras ventajas incluyen la farmacología más predecible, menos interacciones entre medicamentos y farmacocinética menos compleja. La universidad busca socios en la industria farmacéutica con el fin de establecer acuerdos de licencia e investigación para avanzar en este tratamiento.



Details

Tittle:
Dual- and triple-target drugs for the treatment of central nervous system diseases
Summary:
A German university has developed a new potent dual- and triple-target drug for the treatment of diseases in the central nervous system (CNS). This invention has improved compliance including less side effects and reduced toxity. The German university offers a license agreement in the pharmaceutical sector as well as a research cooperation in order to advance this treatment.
Description:
Adenosine is a modulator of many physiological and pathophysiological processes in the central nervous system (CNS). Blockade of the adenosine receptors A1ARs and A2AARs has shown beneficial neuroprotective effects in animal models and in clinical studies of Parkinsons´s disease (PD) and Alzheimer´s disease (AD).
Furthermore, selective inhibitors of the monoamine oxidase A (MAO-A) are applied as adjunctive therapeutics for PD, as they protect the brains of PD patients from oxidative stress.

Nevertheless, there is still no satisfactory multitarget drug approach which inhibits MAO-A and the two adenosine receptors A1ARs and A2AARs.

A German university provides newly designed tricyclic xanthine derivatives which allow overcoming this problem. A variety of 69 derivatives were prepared and evaluated in radioligand binding studies at adenosine receptors and for their ability to inhibit monoamine oxidases. Potent dual-target-directed A1/A2A adenosine receptor antagonists were identified. Several compounds even showed triple-target inhibition.

Together, these observations position tricyclic xanthine derivatives as ideal candidates for the treatment of neurodegenerative diseases such as PD and AD, but might also be suitable for the treatment of depression, addiction and restless legs syndrome.

The German university is now looking for a license agreement or research cooperation in the pharmaceutical sector.
Advantages and Innovations:
- New potent dual- and triple target drugs for the treatment of PD and AD

- Multi-target drug with
- Improved compliance
- Less side effects
- Reduced toxicity

- Significant advantages over combination therapy
- More predictable pharmacology
- Reduced drug-drug interactions
- Less complex pharmakokinetics
Stage of Development:
Field tested/evaluated
IPs:
Patents granted
CommeR Statunts Regarding IPR Status:
Patents granted for Germany, Great Britain and France

Partner sought

Type and Role of Partner Sought:
The German university has two opportunities for cooperation in mind:
- they offer a license agreement or looks for a buyer of the drug
- they offer a research cooperation agreement for the further development of the drug (especially for the clincal development)

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06001012 Investigaciones médicas
06001015 Productos farmacéuticos / medicamentos